There is a novel & very promising investigational drug/ vaccine being tested right now (in clinical trial) with great hope of improving outcomes for patients with Glioblastoma Multiforme, the most malignant type of brain tumor. It’s called Heat Shock Protein Peptide Complex-96 (HSPPC-96).
Here’s the dealio (as my daughter always says)… HSPPC-96 is a protein that is made from a patient’s own tumor. The vaccine is prepared “tumor specific” and provokes the body’s disease-fighting response. When injected into a patient, this vaccine causes the body’s immune system to attack cancer cells. This is yet another example of how personalized medicine is revolutionizing cancer care.
HSPPC-96 represents a novel, promising, and exciting new avenue for brain tumor therapy. This vaccine has had promising results for other types of cancer as well. In fact, a review of data from a recent study of HSPPC-96 in kidney cancer has begun. More than 700 patients were enrolled in this study and a total of 318 received at least one injection with HSPPC-96. On average, it appeared that it takes longer for the cancer to come back in patients treated with HSPPC-96 compared to patients who did not receive HSPPC-96. Also, the study showed that patients with less severe disease that were treated with HSPPC-96 lived without the disease coming back for more than 1.5 years longer than those patients who were not treated with HSPPC-96.
There are currently 11 medical centers studying the HSPPC-96 Vaccine: Miami; Johns Hopkins, Duke, UCSF, Mayo, Yale, Columbia, UPenn, Case Western, Oklahoma & Northwestern. For more information on how this novel approach works, read this article from the Journal of the National Cancer Institute. And of course, speak with your oncologist & neurosurgeon.
Thank you to Dr. Rick Komotar, Neurosurgeon Extraordinaire, for sharing this info with me!!! (You’re the BEST Dr. K)